130115-85-4 Usage
General Description
2-Chloro-3-Bromo-5-Hydroxypyridine is an organic compound with the chemical formula C5H3ClBrNO. It is a heterocyclic compound with a pyridine ring substituted with chloro, bromo, and hydroxy groups. 2-Chloro-3-Bromo-5-Hydroxypyridine is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It has potential applications in the synthesis of antiviral and antimicrobial agents. Additionally, it is used as an intermediate in the production of various organic compounds and can also be used as a reagent in chemical reactions. 2-Chloro-3-Bromo-5-Hydroxypyridine is typically handled and stored with care due to its toxic and potentially harmful properties.
Check Digit Verification of cas no
The CAS Registry Mumber 130115-85-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,0,1,1 and 5 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 130115-85:
(8*1)+(7*3)+(6*0)+(5*1)+(4*1)+(3*5)+(2*8)+(1*5)=74
74 % 10 = 4
So 130115-85-4 is a valid CAS Registry Number.
InChI:InChI=1/C5H3BrClNO/c6-4-1-3(9)2-8-5(4)7/h1-2,9H
130115-85-4Relevant articles and documents
MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS
-
Paragraph 0775, (2020/10/09)
The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
-
, (2008/06/13)
A series of 3-pyrrolidinyloxy-3′-pyridyl ether compounds, a method for selectively controlling neurotransmitter release in mammals using these compounds, and pharmaceutical compositions including these compounds. Preferred compounds are 3-pyrrolidinylmethoxy-3′-(5′-and/or 6′-substituted) pyridyl ethers.
